Trial Profile
A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Infantile-Onset Pompe Disease with One Year Alglucosidase Alfa Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Therapeutic Use
- Acronyms APOLLO-IOPD
- Sponsors Sanofi China Investment
- 13 Jul 2021 Status changed from active, no longer recruiting to completed.
- 11 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Dec 2018 Status changed from not yet recruiting to recruiting.